Comparative Pharmacology
Head-to-head clinical analysis: FERROUS CITRATE FE 59 versus MACROTEC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FERROUS CITRATE FE 59 versus MACROTEC.
FERROUS CITRATE FE 59 vs MACROTEC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ferrous citrate Fe 59 is a radioactive isotope of iron used for diagnostic purposes. It is incorporated into hemoglobin in red blood cells, allowing visualization of erythropoiesis and imaging of the reticuloendothelial system.
Not applicable for diagnostic use.
Ferrous citrate Fe 59 is a radioactive diagnostic tracer, not a therapeutic iron supplement. Typical adult dose: 2-10 µCi (0.074-0.37 MBq) intravenously as a single dose for iron absorption or red cell utilization studies.
5 mCi (185 MBq) intravenously as a single dose for lung perfusion imaging.
None Documented
None Documented
Terminal elimination half-life of Fe-59 from plasma is approximately 1.5-2 hours for free iron, but for total body iron, it is about 5-6 hours initially, followed by a slow phase of 6-10 days due to redistribution to storage sites. Clinically, the long half-life allows imaging of erythropoiesis over days.
6 hours; prolonged in renal impairment (up to 30 hours in ESRD)
Fe-59 is primarily excreted via feces (80-90%) as unabsorbed iron, with minor renal excretion (<5%) and negligible biliary elimination. Absorbed iron is incorporated into hemoglobin and red blood cells, with loss via desquamation (~1 mg/day) not reflected in excretion fractions.
Renal: 95% as unchanged drug; biliary/fecal: <5% as metabolites
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical